Filament Health

We are proud to announce positive data from a phase 2 study of PEX010 in patients with alcohol use disorder. The open-label study at Psykiatrisk Center København found that alcohol consumption significantly decreased amongst participants dosed with Filament’s botanical psilocybin drug candidate. After a single dose of PEX010, the mean percentage of heavy drinking days was reduced by more than 50% over the 12-week observation period. From our CEO, Benjamin Lightburn: “We are thrilled to announce positive results which support the efficacy of PEX010. These data reinforce our confidence in the potential of botanical psilocybin to help the millions of people suffering from substance use disorders like AUD. We look forward to advancing to the next stage of development.” https://lnkd.in/gv-zQP8B

Benjamin Lightburn was a guest on the Causes or Cures Podcast and spoke to ErinKate Stair about how Filament develops natural psychedelic medicines and insights into early results from our clinical trials at leading academic research institutions.

Filament Health recently shipped its botanical #psilocybin #drug candidate, PEX010, to the University of Wisconsin-Madison for investigation in two #clinicaltrials. The FDA-authorized trials will study the effects of psilocybin on neuroplasticity, which refers to the ability of the brain to adapt to new situations. "Our goal with this research is to examine how psilocybin's effects on neuroplasticity may impact participants' wellbeing and their ability to understand the world around them," said Charles Raison, MD, principal investigator of both clinical trials and professor of #psychiatry at the UW School of Medicine and Public Health. Both clinical trials are expected to begin in Q1 2025. Press Release: 'Filament Health announces shipment of botanical psilocybin to the University of Wisconsin–Madison' https://lnkd.in/gw8BF2sg via Cision #university #Wisconsin #psychedelics #mentalhealth #clinicalresearch #FDA

We are pleased to announce that our botanical psilocybin drug candidate, PEX010, has been shipped to the University of Wisconsin-Madison for investigation in two clinical trials. Both trials are FDA-authorized and will study the effects of psilocybin on neuroplasticity. From Dr. Charles Raison, principal investigator: “Our goal with this research is to examine how psilocybin’s effects on neuroplasticity may impact participants’ wellbeing and their ability to understand the world around them." https://lnkd.in/gjekqpBM

Benjamin Lightburn spoke to Daniel Levine on The Bio Report podcast about Filament's novel approach to psychedelic medicine - developing botanical drug candidates from plants and fungi, instead of synthetics.

Today we announced the import of coca leaf from Peru to Filament's Metro Vancouver R&D facility. The import was completed by our joint venture, Magdalena Biosciences, which was founded to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder in adults. The coca leaf will be used for the development of a botanical drug candidate for the treatment of ADHD, and other possible therapeutic indications. https://lnkd.in/gSX5ptS4

We're pleased to announce that researchers at Imperial College London will study the effects of our botanical psilocybin drug candidate, PEX010, for opioid use disorder in a groundbreaking clinical trial funded by the NIHR (National Institute for Health and Care Research). https://lnkd.in/eyPDS7bg

Today we announced a major expansion of our intellectual property portfolio, with 12 new patents accepted in Australia, 5 in Canada, and 3 in the United States. Filament's industry-leading IP portfolio contains 46 allowed patents relating to the extraction, purification, standardization, and delivery of naturally-derived psychedelic APIs. From our CEO Benjamin Lightburn: “As the premier global supplier of cGMP botanical psilocybin, the protection of Filament’s drug candidates and intellectual property is critical for the distribution of our drug products to support clinicians, patients, and the continuation of psychedelic research and development around the world. We are pleased to see that our innovative technology continues to be recognized internationally.” https://lnkd.in/gxtPhMds

We're proud to supply the SAP with our botanical psilocybin so that Canadian patients receive much-needed access.

Today we announced the authorization by both FDA and Health Canada | Santé Canada of a Phase 2 clinical trial studying PEX010 for methamphetamine use disorder (MAUD). This will be the first ever clinical trial to study the safety and efficacy of botanical psilocybin in a MAUD patient population. From Principal Investigator, Dr. Christian G. Schütz: “Existing clinical data indicates that psilocybin shows promise for the treatment of MAUD. Our aim with this trial is to assess the safety and efficacy of PEX010 in the treatment of MAUD, and to evaluate changes in participants’ substance use, cravings, motivation, and recovery capital. We are grateful to Filament Health for funding and facilitating this much-needed research.” We are also pleased to announce a C$1 million bridge financing with Negev Capital and our CEO Benjamin Lightburn, which will facilitate the continued advancement of our clinical development programs. https://lnkd.in/gAcbVafM